Deirdra R Terrell

List of Publications by Year
in descending order

98 papers	6,142 citations	76196 40 h-index	71532 76 g-index
98 all docs	98 docs citations	98 times ranked	4073 citing authors

#	Article	IF	Citations
1	American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances, 2019, 3, 3829-3866.	2.5	684
2	Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood, 2004, 104, 2623-2634.	0.6	561
3	Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2010, 115, 1500-1511.	0.6	477
4	The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. American Journal of Hematology, 2010, 85, 174-180.	2.0	308
5	Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood, 2015, 125, 616-618.	0.6	282
6	Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion, 2004, 44, 294-304.	0.8	219
7	Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Advances, 2017, 1, 590-600.	2.5	207
8	Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical features. Pediatric Blood and Cancer, 2013, 60, 1676-1682.	0.8	193
9	Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood, 2013, 122, 2023-2029.	0.6	161
10	Platelet Counts during Pregnancy. New England Journal of Medicine, 2018, 379, 32-43.	13.9	157
11	Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion, 2006, 46, 154-156.	0.8	131
12	The Oklahoma thrombotic thrombocytopenic Purpura-Hemolytic uremic syndrome (TTP-HUS) registry: a community perspective of patients with clinically diagnosed TTP-HUS. Seminars in Hematology, 2004, 41, 60-67.	1.8	125
13	Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion, 2004, 44, 1149-1158.	0.8	124
14	Disseminated Malignancy Misdiagnosed as Thrombotic Thrombocytopenic Purpura: A Report of 10 Patients and a Systematic Review of Published Cases. Oncologist, 2007, 12, 11-19.	1.9	117
15	Management of Adult Patients with Persistent Idiopathic Thrombocytopenic Purpura Following Splenectomy. Annals of Internal Medicine, 2004, 140, 112.	2.0	114
16	Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 873-887.	0.8	99
17	Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2016, 127, 3092-3094.	0.6	99
18	The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica, 2019, 104, 2107-2115.	1.7	99

#	Article	IF	Citations
19	<scp>D</scp>rugâ€induced thrombotic microangiopathy: <scp>E</scp>xperience of the <scp>O</scp>klahoma registry and the BloodCenter of <scp>W</scp>isconsin. American Journal of Hematology, 2015, 90, 406-410.	2.0	95
20	Systemic infections mimicking thrombotic thrombocytopenic purpura. American Journal of Hematology, 2011, 86, 743-751.	2.0	87
21	Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolyticâ€uremic syndromes. American Journal of Hematology, 2010, 85, 844-847.	2.0	75
22	Prevalence of primary immune thrombocytopenia in Oklahoma. American Journal of Hematology, 2012, 87, 848-852.	2.0	75
23	Fatigue in adult patients with primary immune thrombocytopenia. European Journal of Haematology, 2011, 86, 420-429.	1.1	74
24	Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 1092-1101.	0.8	73
25	Complications of plasma exchange in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a study of 78 additional patients. Transfusion, 2003, 43, 415-416.	0.8	69
26	Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica, 2012, 97, 297-303.	1.7	69
27	Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood, 2016, 128, 2175-2178.	0.6	68
28	Corticosteroid sideâ€effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. European Journal of Haematology, 2009, 83, 175-182.	1.1	64
29	Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpuraâ€hemolytic uremic syndrome, 1996 to 2011 (CME). Transfusion, 2012, 52, 2525-2532.	0.8	63
30	Longâ€term deficits in healthâ€related quality of life after recovery from thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 118-124.	0.8	61
31	Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood, 2014, 123, 1674-1680.	0.6	61
32	Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. American Journal of Hematology, 2015, 90, 709-714.	2.0	59
33	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. Blood Advances, 2022, 6, 664-671.	2.5	53
34	Sporadic bloody diarrhoeaâ€associated thrombotic thrombocytopenic purpuraâ€haemolytic uraemic syndrome: an adult and paediatric comparison. British Journal of Haematology, 2008, 141, 696-707.	1.2	50
35	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Advances, 2021, 5, 3951-3959.	2.5	49
36	Frequency and Significance of HIV Infection among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura. Clinical Infectious Diseases, 2009, 48, 1129-1137.	2.9	48

#	Article	IF	Citations
37	Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. American Journal of Hematology, 2003, 73, 135-140.	2.0	47
38	Thrombocytopenia as an adverse effect of complementary and alternative medicines, herbal remedies, nutritional supplements, foods, and beverages*. European Journal of Haematology, 2010, 84, 421-429.	1.1	46
39	Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. Annals of Hematology, 2016, 95, 1077-1087.	0.8	43
40	Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005 to 2008. Transfusion, 2009, 49, 392-394.	0.8	42
41	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Advances, 2022, 6, 4915-4923.	2.5	42
42	The Oklahoma Thrombotic Thrombocytopenic Purpuraâ€"Hemolytic Uremic Syndrome Registry: the Swiss connection. European Journal of Haematology, 2008, 80, 277-286.	1.1	40
43	Twiceâ€daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion, 2008, 48, 349-357.	0.8	38
44	Lessons learned from the Oklahoma Thrombotic Thrombocytopenic Purpuraâ€Hemolytic Uremic Syndrome Registry. Journal of Clinical Apheresis, 2008, 23, 129-137.	0.7	38
45	Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. Presse Medicale, 2012, 41, e177-e188.	0.8	35
46	A support group for patients who have recovered from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): The six-year experience of the Oklahoma TTP-HUS Study Group. Journal of Clinical Apheresis, 2003, 18, 16-20.	0.7	28
47	Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion, 2011, 51, 2237-2243.	0.8	27
48	First symptoms in patients with thrombotic thrombocytopenic purpura: what are they and when do they occur?. Transfusion, 2013, 53, 235-237.	0.8	24
49	Drug-induced thrombocytopenia in children. Pediatric Blood and Cancer, 2013, 60, 1975-1981.	0.8	21
50	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. Blood Advances, 2022, 6, 4975-4982.	2.5	21
51	Novel thrombopoietic agents: a new era for management of patients with thrombocytopenia. Haematologica, 2008, 93, 1445-1449.	1.7	20
52	Immune Thrombocytopenia (ITP): Current Limitations in Patient Management. Medicina (Lithuania), 2020, 56, 667.	0.8	20
53	Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial. Transfusion, 2017, 57, 2532-2538.	0.8	18
54	Platelet sequestration and consumption in the placental intervillous space contribute to lower platelet counts during pregnancy. American Journal of Hematology, 2019, 94, E8-E11.	2.0	17

#	Article	IF	Citations
55	Quinine Allergy Causing Acute Severe Systemic Illness: Report of 4 Patients Manifesting Multiple Hematologic, Renal, and Hepatic Abnormalities. Baylor University Medical Center Proceedings, 2003, 16, 21-26.	0.2	16
56	Plasma exchange complications in patients treated for thrombotic thrombocytopenia purpura-hemolytic uremic syndrome: 2011 to 2014. Transfusion, 2014, 54, 3257-3259.	0.8	16
57	A user guide to the American Society of Hematology clinical practice guidelines. Blood Advances, 2020, 4, 2095-2110.	2.5	14
58	Is immune thrombocytopenic purpura less common among black Americans?. Blood, 2005, 105, 1368-1369.	0.6	13
59	Management of Primary Immune Thrombocytopenia, 2012: A Survey of Oklahoma Hematologists-Oncologists. American Journal of the Medical Sciences, 2014, 347, 190-194.	0.4	13
60	Support groups for patients who have recovered from thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 2008, 23, 168-169.	0.7	12
61	Addendum to corticosteroid side effects and risk for bleeding in immune thrombocytopenic purpura: patient perspectives. European Journal of Haematology, 2009, 83, 497-498.	1.1	11
62	Validation of claims-based diagnostic codes for idiopathic thrombotic thrombocytopenic purpura in a commercially-insured population. Thrombosis and Haemostasis, 2010, 103, 1203-1209.	1.8	11
63	Determining a definite diagnosis of primary immune thrombocytopenia by medical record review. American Journal of Hematology, 2012, 87, 843-847.	2.0	11
64	Management of antithrombotic therapy in adults with immune thrombocytopenia (ITP): a survey of ITP specialists and general hematologistâ€“oncologists. Journal of Thrombosis and Thrombolysis, 2018, 46, 24-30.	1.0	11
65	The Incidence of TTP-HUS: Racial Disparity among Patients with Severe ADAMTS13 Deficiency.. Blood, 2004, 104, 857-857.	0.6	11
66	Successful treatment of cyclic thrombocytopenia with thrombopoietinâ€mimetic agents: A report of two patients. American Journal of Hematology, 2009, 84, 459-461.	2.0	10
67	Referral of patients with thrombocytopenia from primary care clinicians to hematologists. Blood, 2009, 113, 4126-4127.	0.6	8
68	Depression in adult patients with primary immune thrombocytopenia. American Journal of Hematology, 2016, 91, E462-3.	2.0	8
69	The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: a community service. Journal - Oklahoma State Medical Association, 2007, 100, 273-8.	0.4	8
70	Health care utilization of patients diagnosed with idiopathic thrombotic thrombocytopenic purpura in a commercially insured population in the United States. Transfusion, 2012, 52, 1614-1621.	0.8	6
71	Thrombotic thrombocytopenic purpura patients' attitudes toward depression management: A qualitative study. Health Science Reports, 2019, 2, e136.	0.6	6
72	Predicting Risk for Relapse in Patients Who Have Recovered from Thrombotic Thrombocytopenic Purpura (TTP).. Blood, 2006, 108, 91-91.	0.6	4

#	Article	IF	Citations
73	Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura. PLoS ONE, 2015, 10, e0117614.	1.1	4
74	Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura. Blood, 2022, 140, 785-789.	0.6	4
75	Thrombotic Thrombocytopenic Purpura (TTP) and Systemic Lupus Erythematosus (SLE): Distinct but Potentially Overlapping Syndromes.. Blood, 2004, 104, 858-858.	0.6	3
76	Evidence for a Pathophysiological Role of Anti-ADAMTS13 Antibodies Despite the Presence of Normal ADAMTS13 Activity and Presumption of an Epitope Spreading over Time in Recurrent Thrombotic Thrombocytopenic Purpura (TTP).. Blood, 2006, 108, 1067-1067.	0.6	3
77	Neurocognitive Impairment Following Recovery from ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP).. Blood, 2007, 110, 1311-1311.	0.6	3
78	The Prevalence of Immune Thrombocytopenic Purpura (ITP).. Blood, 2008, 112, 1277-1277.	0.6	3
79	Long-Term Follow-Up of 21 Patients with Thrombotic Thrombocytopenic Purpura (TTP) and Severe ADAMTS13 Deficiency: Demonstration of Persistent ADAMTS13 Deficiency and Neurocognitive Abnormalities.. Blood, 2004, 104, 856-856.	0.6	2
80	Long-Term Abnormalities of Patient-Reported Outcomes after Recovery from Thrombotic Thrombocytopenic Purpura (TTP) Using Health Related Quality-of-Life (QOL) Measurements.. Blood, 2006, 108, 458-458.	0.6	2
81	Sporadic Bloody Diarrhea-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) in Adults in Oklahoma: Comparison to Adults with Severe Adamts13 Deficiency and to Children with Typical HUS.. Blood, 2007, 110, 1317-1317.	0.6	2
82	Drug-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS): Frequency, Presenting Features, and Clinical Outcomes.. Blood, 2007, 110, 1315-1315.	0.6	2
83	Impact of Residual Effects and Complications of Thrombotic Thrombocytopenic Purpura (TTP) on Daily Living: A Qualitative Study. Blood, 2019, 134, 931-931.	0.6	2
84	Longâ€term outcomes of healthâ€related quality of life following diverse thrombotic microangiopathy syndromes. American Journal of Hematology, 2016, 91, E278-9.	2.0	1
85	The Frequency of Rheumatic Disease Autoantibodies in Patients with ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP).. Blood, 2007, 110, 2090-2090.	0.6	1
86	Thrombotic Thrombocytopenic Purpura (TTP) Patient Attitudes Regarding Depression Management: a Qualitative Study. Blood, 2014, 124, 203-203.	0.6	1
87	Self-Injection of Romiplostim by Patients with Chronic Immune Throbocytopenic Purpura (ITP). Blood, 2008, 112, 4707-4707.	0.6	1
88	Incidence, Age, and Gender of Children with Thrombotic Thrombocytopenic Purpura (TTP) Associated with Severe, Acquired ADAMTS13 Deficiency.. Blood, 2012, 120, 2196-2196.	0.6	1
89	Genotype-Phenotype Correlation in Congenital TTP: New Insights from a Multicentre Study with 121 Patients. Blood, 2018, 132, 376-376.	0.6	1
90	Detecting Drugs That Cause Thrombocytopenia: A Comparison of Published Case Reports and Data Mining of the US FDA Adverse Event Reporting System (AERS) Database.. Blood, 2006, 108, 462-462.	0.6	0

#	Article	IF	Citations
91	Disseminated Malignancy Misdiagnosed as Thrombotic Thrombocytopenic Purpura: A Report of 10 Patients and a Systematic Review of Published Cases.. Blood, 2006, 108, 1062-1062.	0.6	0
92	Clinical Outcomes in Patients with ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura (TTP) Who Received Platelet Transfusions (PT).. Blood, 2007, 110, 1302-1302.	0.6	0
93	What Level of Platelet Count and Symptoms Trigger Referral of Patients with Thrombocytopenia from Primary Care Physicians to Hematologists?. Blood, 2008, 112, 4692-4692.	0.6	0
94	Elevated Serum Type I Interferon Activity and Type I Interferon Peripheral Blood Gene Signature In a Subset of Patients with Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura.. Blood, 2010, 116, 3694-3694.	0.6	0
95	Quinine-Induced Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS): Characteristic Clinical Presentation and High Risk for Chronic Kidney Disease (CKD). Blood, 2011, 118, 2216-2216.	0.6	0
96	A case report of long-term complete remission following cessation of romiplostim dosing in a previously severe ITP patient.. Journal of Clinical Oncology, 2012, 30, e17001-e17001.	0.8	0
97	Management of Primary Immune Thrombocytopenia, 2012: A Survey of Oklahoma Hematologists-Oncologists. Blood, 2012, 120, 1094-1094.	0.6	0
98	The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: Key findings at Enrolment until 2017. Hamostaseologie, 2020, 40, .	0.9	0